Drug – bio-affecting and body treating compositions – Lymphokine – Interleukin
Patent
1994-08-12
1996-04-16
Walsh, Stephen G.
Drug, bio-affecting and body treating compositions
Lymphokine
Interleukin
530351, A61K 3820, C07K 1455
Patent
active
055080316
ABSTRACT:
Damage to cells, tissue and other body parts in a mammalian host may be treated by using a lymphokine or cytotoxin in conjunction with at least one biological modifier, which may be a free radical scavenger or a metabolic inhibitor. The biological modifier is preferably uric acid, buthionine sulphoximine, vitamin C, aspirin, or nordihydroguaiaretic acid. Such a combination may be used to treat, for example, cancer, infectious diseases, and damage caused by radiation therapy, high oxygen tension, and chemotherapy.
REFERENCES:
patent: 4645830 (1987-02-01), Yasushi et al.
patent: 4762705 (1988-08-01), Rubin
patent: 4962091 (1990-10-01), Eppstein et al.
patent: 4985241 (1991-01-01), Zimmerman et al.
patent: 5021239 (1991-06-01), Garnick
Hird in "Genes and Cancer" (D. Canney & K. Bikora, Eds.) John Wiley & Sons, New York (1990), pp. 183-189.
Chun et al (1985) Scound J. Immunol. 22, 375-381.
Aoki et al (1984) Immunol. Lett. 7, 321-324.
Adams et al., "Plasma Glutathione and Glutathione Disulfide in the Rat: Regulation and Response to Oxidative Stress," J. Pharmacol. Exp. Ther., 227:749-754 (1983).
Alexander et al., "Synergistic Enhancement by tumor Necrosis Factor of in Vitro Cytotoxicity from Chemotherapeutic Drugs Targeted at DNA Topisomerase II," Cancer Research, 47:2403-2406 (1987).
Almqvist et al., "Treatment of Experimental Canine Endotoxin Shock with Ibuprofen, a Cyclooxygenase Inhibitor," Circulatory Shock, 13:227-232 (1984).
Ames et al., "Uric acid provides an antioxidant defense in humans against oxidant-and readical-caused aging and cancer: A hypothesis," PNAS (USA), 78:6858-6862 (1981).
Andrews et al., "Differential Potentiation of Alkylating and Platinating Agent Cytotoxicity in Human Ovarian Carcinoma Cells by Glutathione Depletion," Cancer Res., 45:6250-6253 (1985).
Arrick et al., "Inhibition of Glutathione Synthesis Augments Lysis of Murine Tumor Cells by Sulfhydryl-reactive Antineoplastics," J. Clin. Invest., 71(2).258-267 (1983).
Bachwich et al., "Tumor Necrosis Factor Stimulates Interleukin-1 and Prostaglandin E.sub.2 Production in Resting Macrophages," Biochemical and Biophysical Research Communications, 136:94-101 (1986).
Badwey and Karnovsky, "Active Oxygen Species And The Functions Of Phagocyltic Leukocytes," Ann. Rev. Biochem., 49:695-726 (1980).
Balkwill et al., "Human Tumor Xenografts Treated with Recombinant Human Tumor Necrosis Factor Alone or in Combination with Interferons," Cancer Research, 46:3990-3993 (1986).
Bus and Gibson, "Lipid Peroxidation And Its Role In Toxicology," Rev. Biochm. Toxicol., (Hodgson et al., Eds.)., Elsevier, North Holland, pp. 125-149 (1979).
Cerutti et al., "Membrane-Mediated Chromosomal Damage," Genes And Proteins In Oncogenesis, (Academic Press, NY)., pp. 55-67 (1983).
Crook et al., "Glutathione Depletion as a Determinant of Sensitivity of Human Leukemia Cells to Cyclophosphamide," Cancer Res., 46:5035-5038 (1986).
DiGuiseppi et al., "The Toxicology Of Molecular Oxygen," CRC Crit. Rev. Toxicol., 12:315-342 (1984).
Dorr et al., "Cytotoxic effects of glutathione synthesis inhibition by L-buthionine-(SR).-sulfoximine on human and murine tumor cells," Invest. New Drugs, 4:305-313 (1986).
Fridovich, "The Biology of Oxygen Radicals," Science, 201:875-880 (1978).
Green et al., "Potentiation of Melphalan Cytotoxicity in Human Ovarian Cancer Cell Lines by Glutathione Depletion," Cancer Res., 44:5427-5431 (1984).
Hamilton et al., "Augmentation of Adriamycin, Melphalan, and Cisplatin Cytotoxicity in Drug-Resistant and Sensitive Human Ovarian Carcinoma Cell Lines by Buthionine Sulfoximine Mediated Glutathione Depletion," Biochem. Pharmacol., 34(14):2583-2586 (1985).
Hodgkiss and Middleton, "Effects of Glutathione Depletion Using Buthionine Sulphoximine on the Cytotoxicity of Nitroaramoatic Compounds in Mammalian Cells In Vitro," Biochem. Pharmacol., 34:2175-2178 (1985).
Kawakami et al., "Cachectin/TNF as well as Interleukin-1 Induces Prostacyclin Synthesis in Cultures Vascular Endothelial Cells," Biochemical and Biophysical Research Communications, 141:482-487 (1986).
Kull and Cuatrecasas, "Possible Requirement of Internalization in the Mechanism of in Votro Cytoxicity in Tumor Necrosis Serum," Cancer Research, 41:1885-4890 (1981).
Kunkel et al., "Regulation of Macrophage Tumor Necrosis Factor Production by Prostaglandin E.sub.2," Biochemical and Biophysical Research Communications, 137:404-410 (1986).
Larrick et al., "Recombinant Tumor Necrosis Factor Causes Activation of Human Granulocytes," Blood, 69:640-644 (1987).
Lesko et al., "Role of Superoxide in Deoxyribonucleic Acid Strand Scission," Biochemistry, 19:3023 (1980).
Marcus et al., "Serve Hypovitaminosis C Occuring as the Result of Adoptive Immunotherapy with High-Dose Interleukin 2 and Lymphokine-activated Killer Cells," Cancer Research, 47:4028-4212 (1987).
Meister and Anderson, "Glutathione," Ann. Rev. Biochem., 52:711-760 (1983).
Minchinton et al., "Glutathione Depletion in Tissues After Administration of Buthionine Sulphoximine," Int. J. Radiation Oncology Biol. Phys., 10:1261-1264 (1984).
Moody and Hassan, "Mutagenicity of oxygen free radicals," PNAS (USA), 79:2855-2859 (1982).
Morin and Ballet, "A recent overview on in vitro and in vivo immunological activities of methisoprinol," Allergol. Immunopathol., 10:109-114 (1982).
Neta et al., "Interleukin 1 Is A Radioprotector," J. Immunol., 136:2483-2485 (1986).
Ono et al., "Combined effect of buthionine sulfoximine and cyclophosphamide upon murine tumours and bone marrow," Br. J. Cancer (UK)., 54:749-754 (1986).
Ozols, "Pharmacologic Reversal of Drug Resistance in Ovarian Cancer," Semin. Oncol., 12:7-11 (1985).
Ozols et al., "Glutathione Depletion With Buthionine Sulfoximine: Potential Clinical Applications," Devel. Oncol., 47:277-293 (1986).
Palladino et al., "Tumor Necrosis Factor-Alpha And Interferon-Gamma Induce Neutrophils From Normal And Chronic Granulomatous Disease Patients To Release Superoxide," Clin. Res., 34:502 (1986).
Palladino et al., ".gamma.Irradiation-induced mortality: protective effect of protease inhibitors in chickens and mice," Int. J. Radiat. Biol., 41:183-191 (1982).
Petkau, "Radiation carcinogenesis from a membrane Perspective," Acta. Physiol. Scand. Suppl., 492:81-90 (1980).
Romine and Kessel, "Intracellular Glutathione As A Determinant Of Responsiveness To Antitumor Drugs," Biochem. Phrmacol. (UK)., 35(19).:3323-3326 (1986).
Ruff and Gifford, "Rabbit Tumor Necrosis Factor: Mechanism of Action," Infection and Immunity, 31:380-385 (1981).
Russo et al., "The Roles Of Intracellular Glutathione in Antineoplastic Chemotherapy," Int. J. Radiat. Oncol. Biol. Phys., 12:1347-1354 (1986).
Russo et al., "Selective Modulation of Glutathione Levels in Human Normal versus Tumor Cells and Subsequent Differential Response to Chemotherapy Drugs," Cancer Res., 46:2845-2848 (1986)
Slater, "Free-radical mechanisms in tissue injury," Biochem. J., 222:1-15 (1984).
Somfai-Relle et al., "Reduction in cellular glutathione by buthionine sulfoximine and sensitization of murine tumor cells resistant to L-phenylalanine mustard," Biochem. Pharmacol., 33:485-490 (1984).
Svedersky, "Enhanced Antitumor Activity Of Recombinant IFN-Gamma In Combination With Tumor Necrosis Factors And Chemotherapeutic Agents," Int. J. of Immunopharm., 7(3).:330 (1985).
Tew et al., "Relationship of Glutathione Depletion and Inhibition of Glutathione-S-Transferase Activity to the Antimitotic Properties of Estramustine," Cancer Treatment Rep., 70:715-720 (1986).
Tomasz, "H.sub.2 O.sub.2 Generation During the Redox Cycle of Mitomycin C and DNA-Bound Mitomycin C," Chem. Biol. Interact., 13:89-97 (1976).
Wang and Hanson, "Parenteral Formulations of Proteins and Peptides: Stability and Stabilizers," J. Parenteral Sci. Tech., 42:s1-s26 (1988).
Whloher and Evans, "Cytokines in Disease," Clin. Chem, 36:1269-1281 (1990).
Aune and Pogue, "Inhibition of Tumor Cell Growth by Interferon-.gamma. is Mediated by Two Distinct Mechanisms Dependant upon Oxygen Tension: Induction of Tryptophan Degradation and Depletion of Intracellular Nicotinamide Adenine Dinucleotide" J. Cl
Marafino, Jr. Benedict J.
Zimmerman Robert
Blackburn Robert P.
Cetus Oncology Corporation
Gass David A.
Savereide Paul B.
Walsh Stephen G.
LandOfFree
Method for treating biological damage using a free-radial scaven does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating biological damage using a free-radial scaven, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating biological damage using a free-radial scaven will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-323621